Cell & Gene provides actionable information to professionals involved in the development and commercialization of cell and gene therapies. Through the original editorial published on the site — both staff-written and contributed (by subject-matter experts) — Cell & Gene facilitates the sharing of insights on challenges, trends, and best practices in this burgeoning field. Cell & Gene’s editorial scope spans the entire product lifecycle from basic research to commercialization.

Life Science Innovation looked at vaccine manufacturing, cell & gene therapy, innovation and clinical trials and featured insightful content from OBN, ABPI, ABHI and MedCity.

The Standards Coordinating Body for Gene, Cell, and Regenerative Medicines and Cell-Based Drug Discovery (SCB) looks to complement the current SDO processes for standards development by engaging regenerative medicine stakeholders to ensure that new or revised standards provide the greatest benefits to the broad regenerative medicine community.

The Maryland Stem Cell Research Fund (MSCRF) is focused on identifying and fostering cutting-edge research and innovation in the field of regenerative medicine in MD. Our Accelerating Cures initiative comprises programs that help transition human stem cell-based technologies from the bench to the bedside as well as mechanisms to build and grow stem cell companies in Maryland. MSCRF has invested over $170 million in accelerating stem cell research, cures and commercialization, in addition to building a collaborative stem cell community in our region. Learn more about our mission and our funding opportunities for any US-based stem cell/cell therapy company.